Flagship Pioneering and Metaphore Biotechnologies Partner with Novo Nordisk to Develop Therapies for Obesity
Shots:
- Metaphore & Flagship Pioneering have teamed up with Novo Nordisk to develop 2 next-generation therapies for obesity under which Metaphore will advance foundational & preclinical activities by jointly working with Pioneering Medicines (Flagship’s drug development unit) & Novo Nordisk
- The collaboration will use Metaphore’s MIMIC platform to discover & develop therapies targeting GLP-1 receptor & related biology for managing obesity
- Moreover, Novo Nordisk will reimburse R&D costs and make a payment of up to $600M as up front, development, & commercial milestones along with annual net-sales-based tiered royalties, shared b/w Metaphore & Pioneering Medicines. It will further participate in upcoming financing rounds for Metaphore
Ref: Metaphore Biotechnologies | Image: Metaphore Biotechnologies
Related News:- Eli Lilly Reports the P-III (SURMOUNT-OSA) Study Data of Tirzepatide in Patients with Obstructive Sleep Apnea (OSA) and Obesity
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
